Codexis to Hold Third Quarter 2020 Conference Call on November 5
Codexis, a leader in protein engineering, is set to announce its third quarter 2020 financial results on November 5, 2020, after market close. The management will host a conference call at 4:30 p.m. ET to discuss these results and provide company updates. Investors are encouraged to pre-register for the call to streamline access. The announcement underlines Codexis' focus on transparency and engagement with its investment community.
- Upcoming third quarter 2020 financial results are anticipated for November 5, showcasing the company's commitment to transparency.
- None.
REDWOOD CITY, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that it will report third quarter 2020 financial results after market close on Thursday, November 5, 2020. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update.
We encourage participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10149420/dbfe0f52b4. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.
Those without internet access or unable to pre-register may dial in by calling:
| U.S. | 844-763-8274 |
| International | 412-717-9224 |
| Passcode | 10149420 |
A live webcast of the call will be available at Codexis IR Website. The webcast will be archived for 90 days.
A replay of the call will be available for 48 hours by calling:
| U.S. | 877-344-7529 |
| Canada | 855-669-9658 |
| International | 412-317-0088 |
| Passcode | 10149420 |
| The replay will be available for 48 hours | |
About Codexis, Inc.
Codexis is a leading protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. For more information, see www.codexis.com.
Contact:
LHA Investor Relations
Jody Cain, 310-691-7100
jcain@lhai.com
FAQ
When will Codexis report its third quarter 2020 financial results?
What time is the Codexis conference call on November 5, 2020?
How can I participate in the Codexis conference call?
Is the Codexis conference call available for replay?
